If you’re keeping score, so far in this npm guide we’ve developed a general understanding of what npm is—notably, that it stands for Node Package Manager. In the process, we’ve discussed the importance of the command line and how it’s …

---

What the Heck is a Package Manager? originally published on CSS-Tricks. You should get the newsletter and become a supporter.

As the novel coronavirus epidemic continues to spread across the globe, WTR provides an updated look at measures that national IP offices have launched in response.

Walgreens COVID-19 Index identifies the spread of current and emerging Covid-19 variants in real-time.

The post Walgreens launches new interactive tool to track Covid-19 variants appeared first on Medical Device Network.

Dubai, UAE January 19 2022 The teaching of financial literacy in schools and homes is crucial to safeguarding teenagers from the money worries plaguing their young adult elders, according to a British teacher-turned-FinTech entrepreneur. Dubai resident Simon Wing says ‘the clock is ticking on plugging a youth financial literacy chasm’. Commenting on findings of the […]

The post Financial Literacy Key To Protecting Next Generation From Money Woes, Says Teacher-Turned-FinTech Entrepreneurs appeared first on Fintech News.

TOKYO, Jan 20, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine. The pivotal study evaluated the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting.

The publication includes previously reported data that was first presented in an oral plenary session at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.(1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Objective response rate (ORR) data and additional detailed efficacy and safety data, including subgroup analyses, are also featured in the publication.

"While rates of endometrial carcinoma continue to rise globally, patients with advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy," said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients."

"The Phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. share in addressing the unmet needs of people living with difficult-to-treat cancers, including advanced endometrial carcinoma," said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology Business Group at Eisai Inc. "The publication of this study in the New England Journal of Medicine reflects the importance of our joint research in exploring the potential of the LENVIMA plus KEYTRUDA combination."

The publication contains results for the all-comer population, including the mismatch repair deficient (dMMR) patient population for which LENVIMA plus KEYTRUDA is not approved in the U.S.

Based on the results from the Phase 3 Study 309/KEYNOTE-775 trial, LENVIMA plus KEYTRUDA has been approved in the U.S. for patients with advanced endometrial carcinoma that is not microsatellite instability-high or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in more than 10 different tumor types across more than 20 clinical trials.

(1) Eisai co., Ltd. Home page. "LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study". https://www.eisai.com/news/2021/news202116.html

Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
Investor Relations:
+81-(0) 70-8688-9685

Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Relations
Melissa Moody: +1-(215) 407-3536
Nikki Sullivan: +1-(718) 644-0730
Investor Relations
Peter Dannenbaum: +1- (908) 740-1037
Raychel Kruper: +1-(908) 740- 2107

For more information, visit https://www.eisai.com/news/2022/news202207.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.

DUBLIN–(BUSINESS WIRE)–The “Global Data Preparation Tools Market By Component, By Function, By Deployment Type, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021 – 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Data Preparation Tools Market size is expected to reach $8.6 billion by 2027, rising at a market growth […]

The post Global Data Preparation Tools Market 2021 – 2027: A $8.6 Billion Market by 2027 – ResearchAndMarkets.com appeared first on Fintech News.

I once read this book called “The Book of Atem” which talks about the existence of “memetic entities”. In essence, the concept explains that memetic entities are thoughtforms that live in multiple people’s minds. For example, Superman is a comic book character that has been interpreted in film, television, comics, mentioned in songs, and so forth. Superman has a backstory and heavy influence on pop culture and if you were to die tomorrow, Superman would continue to live on in the minds of millions of people.

Visual interfaces, augmented analytics, data engineers, analytics cultures, and self-service BI dominate this year’s list.

(PRWeb January 20, 2022)

Read the full story at https://www.prweb.com/releases/bipp_analytics_unveils_predictions_for_the_business_intelligence_and_data_analytics_industry/prweb18445081.htm

The staking infrastructure platform will expand to other L1s to bring convenient, safe staking solutions to retail and institutional funds

(PRWeb January 20, 2022)

Read the full story at https://www.prweb.com/releases/with_12m_strategic_sale_stader_labs_builds_on_terra_success/prweb18444776.htm

Jack Dorsey made headlines by leaving Twitter to focus full-time on Square (now Block) and Bitcoin. But how will the company advance the protocol?

The Space Force is a separate U.S. military branch but will have to stay “tightly coupled” to the Air Force in order to be successful, Air Force Secretary Frank Kendall said Jan. 19. 

SpaceNews

The Norwegian multinational tech company Opera unveiled Web3 crypto internet browser project that will be available to Mac, Windows, and Android users as we can see more today in our crypto latest news. The Opera browser announced a beta version of its new Crypto Browser project. The blog post revealed that the new initiative has […]